Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Hepatitis B Vaccination Among Drug Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 18 and 70 years at the enrolment~* current illicit drug users before drug rehabilitation~* negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) at enrollment~* having spent acute physiological detoxification phase~Exclusion Criteria:~* any intolerance or allergy to any component of the vaccine~* ongoing opportunistic infection~* liver disease~* hemopathy~* cancer~* unexplained fever in the last week before the recruiting

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 60 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
- 20 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
- Control (Type: NO_INTERVENTION): Receive no vaccination during the study period

Based on this trial design, predict the completion outcome and termination type (if applicable).